Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.
Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B. Shiramoto M, et al. Among authors: gruber wc. Hum Vaccin Immunother. 2015;11(9):2198-206. doi: 10.1080/21645515.2015.1030550. Epub 2015 Jul 15. Hum Vaccin Immunother. 2015. PMID: 26176163 Free PMC article. Clinical Trial.
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Juergens C, et al. Among authors: gruber wc. Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27. Hum Vaccin Immunother. 2014. PMID: 24576885 Free PMC article. Clinical Trial.
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
Solanki BB, Juergens C, Chopada MB, Supe P, Sundaraiyer V, Le Dren-Narayanin N, Cutler MW, Gruber WC, Scott DA, Schmoele-Thoma B. Solanki BB, et al. Among authors: gruber wc. Hum Vaccin Immunother. 2017 Sep 2;13(9):2065-2071. doi: 10.1080/21645515.2017.1331796. Hum Vaccin Immunother. 2017. PMID: 28881165 Free PMC article. Clinical Trial.
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR, Klein NP, Downey HJ, Patterson S, Sundaraiyer V, Watson W, Clarke K, Jansen KU, Sebastian S, Gruber WC, Scott DA, Schmöele-Thoma B. Thompson AR, et al. Among authors: gruber wc. Hum Vaccin Immunother. 2019;15(2):444-451. doi: 10.1080/21645515.2018.1533777. Epub 2018 Oct 25. Hum Vaccin Immunother. 2019. PMID: 30303436 Free PMC article. Clinical Trial.
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B, van Cleeff M, Greenberg RN, Gurtman A, Jones TR, Sundaraiyer V, Gruber WC, Scott DA. Schmoele-Thoma B, et al. Among authors: gruber wc. Hum Vaccin Immunother. 2019;15(3):575-583. doi: 10.1080/21645515.2018.1538618. Epub 2019 Jan 16. Hum Vaccin Immunother. 2019. PMID: 30648932 Free PMC article. Clinical Trial.
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, Scott DA; 006 study group. Kieninger DM, et al. Among authors: gruber wc. Vaccine. 2010 Jun 7;28(25):4192-203. doi: 10.1016/j.vaccine.2010.04.008. Epub 2010 Apr 22. Vaccine. 2010. PMID: 20417262 Clinical Trial.
230 results